Synthesis of 9,9-Dialkyl-4,5-diazafluorene Derivatives and Their Structure-Activity Relationships Toward Human Carcinoma Cell Lines

Remote steric control for undirected meta-selective C-H activation of arenes

Regioselective functionalization of arenes remains a challenging problem in organic synthesis. Steric interactions are often used to block sites adjacent to a given substituent, but they do not distinguish the remaining remote sites. We report a strategy based on remote steric control, whereby a roof-like ligand protects the distant para site in addition to the ortho sites, and thereby enables selective activation of meta carbon-hydrogen (C-H) bonds in the absence of ortho or para substituents. We demonstrate this concept for iridium-catalyzed meta-selective borylation of various monosubstituted arenes, including complex drug molecules. This strategy has the potential to expand the toolbox of C-H bond functionalization to previously nondifferentiable reaction sites.

4,5-Diazafluorene N-glycopyranosyl hydrazones as scaffolds for potential bioactive metallo-organic compounds: Synthesis, structural study and cytotoxic activity

A series of novel N¹-(4,5-diazafluoren-9-yliden)-N²-glycopyranosyl hydrazines was prepared in synthetically useful yields by treatment of 9H-4,5-diazafluoren-9-hydrazone with different unprotected monosaccharides. The reactions with the monosaccharides tested afforded stereoselectively, and exclusively, cyclic derivatives, whose structures correspond to N-β-glycopyranosyl hydrazones except for the d-arabinose derivative that agrees with the α-anomer. Several copper(II) complexes having a 2:1 ligand to metal mole ratio were also prepared. The metal complexes can bind DNA sequences and preferentially stabilize G-quadruplex DNA structures over dsDNA. The fucose, rhamnose and deoxyglucose copper(II) complexes exhibited a cytotoxic activity against cultured HeLa and PC3 tumor cells comparable to other metal complexes normally used for chemotherapeutic purposes, such as cisplatin.

Synthesis of platinum(II) and palladium(II) complexes with 9,9-dihexyl-4,5-diazafluorene and their in vivo antitumour activity against Hep3B xenografted mice

Two complexes dichloro(9,9-dihexyl-4,5-diazafluorene)platinum(II) (Pt-DHF) and dichloro(9,9-dihexyl-4,5-diazafluorene)palladium(II) (Pd-DHF) were synthesized and their in vivo antitumour activity was investigated using an athymic nude mice model xenografted with human Hep3B carcinoma cells. Pt-DHF- and Pd-DHF-treated groups showed significant tumour growth inhibition (with about 9-fold and 3-fold tumour growth retardation) when compared with the vehicle control group. The liver toxicology effects on the animals of the two compounds were investigated. Pt-DHF and Pd-DHF-treated groups had a lower alanine transaminase and aspartate transaminase values than those of the vehicle treated group as the animals from the vehicle control group had very heavy hepatoma burden. We assume that both complexes could be further investigated as effective antitumour agents and it is worthwhile to study their underlying working mechanism.

Antifungal study of substituted 4-pyridylmethylene-4′-aniline Schiff bases

Two substituted 4-pyridylmethylene-4′-aniline Schiff bases showed antifungal activity against.Aspergillus nigerandCandida albicans. They may be useful for the development of safe drug candidates forA. nigerandC. albicanscases of otomycosis.

Development of ruthenium(II) complexes as topical antibiotics against methicillin resistant Staphylococcus aureus

A series of ruthenium(II) bis(2,2'-bipyridyl) complexes containing N-phenyl-substituted diazafluorenes (Ru-C1, Ru-C6, Ru-C7 and Ru-F) was synthesized and their potential antibacterial activity against methicillin resistant Staphylococcus aureus (MRSA) was investigated. The Ru-C7 complex showed significant improvement in both minimum inhibitory concentration (MIC, 6.25 μg mL(-1)) and minimum bactericidal concentration (MBC, 25 μg mL(-1)) towards MRSA when compared with those of methicillin (positive control) (MIC = 25 μg mL(-1) and MBC = 100 μg mL(-1)). The Ru-C7 complex possessed much stronger antibacterial effects than the Ru-C6 complex (MIC, 25 μg mL(-1), MBC, >100 μg mL(-1)). Both Ru-C6 and Ru-C7 complexes were also demonstrated to be biologically safe when tested on normal human skin keratinocytes.

Development of Calendula Oil/Chitosan Microcapsules and their Biological Safety Evaluation

Chitosan microcapsules containing calendula oil are prepared by a simple coacervation method. The results show that the performance of the microcapsules, including encapsulation efficiency and particle size, is affected by the change of various processing parameters of microcapsule manufacture. Under the optimal parameter combinations: the chitosan concentration is 1.5 % w/v; the core/wall ratio is 0.1 g mL–1; the stirring speed is 1200 rpm; and the pH value is 10. The compositions and surface morphology of the microcapsules are examined using scanning electron microscope and FTIR spectroscopy. The in vitro cytotoxicity evaluation demonstrates that the microcapsules exhibit no significant cytotoxic effects on human keratinocytes. The in vivo toxicology analysis on mice proves that the microcapsules do not exert any significant necrosis to the liver. It is suggested that our microcapsules could be used as a safe drug carrier both topically and orally.

In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma

We have investigated the potential in vivo anti-tumour activity of corilagin using the Hep3B hepatocellular carcinoma cell line and an athymic nude mice xenograft model. The purity of corilagin was confirmed by high performance liquid chromatographic analysis. Corilagin was administrated intraperitoneally for a continuous period of 7 days at a concentration of 15 mg/kg of body weight per day. A significant inhibition of tumour growth was observed when treated mice are compared with control groups. Furthermore, analysis of enzymes markers of liver function, including alanine aminotransferase and asparate aminotransferase, suggested that current therapeutic dosage of corilagin did not exert adverse effect on liver. Our observations support the view that corilagin is considerably effective to retard the in vivo growth of xenografted Hep3B hepatocellular carcinoma.